Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.

ABSTRACT:

Importance

The US Food and Drug Administration expanded labeling of sacubitril-valsartan from the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (EF) to all patients with HF, noting the greatest benefits in those with below-normal EF. However, the upper bound of below normal is not clearly defined, and value determinations across a broader EF range are unknown.

Objective

To estimate the cost-effectiveness of sacubitril-valsartan vs renin-angiotensin system inhibitors (RASis) across various upper-level cutoffs of EF.

Design, setting, and participants

This economic evaluation included participant-level data from the PARADIGM-HF (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart F

SUBMITTER: Bhatt AS 

PROVIDER: S-EPMC10534998 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature